GlassScriptPhysician profile
Lisa M Esterle
NPI 1427029248
$13,642.42
in general payments reported to CMS, 2019-2025
63 companies · $2,983 in 2025
The $2,983 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $885 · 2021: $1,123 · 2022: $1,600 · 2023: $3,361 · 2024: $2,814 · 2025: $2,983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,157.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,899.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,838.11 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,094.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,001.91 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $837.88 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $606.68 | 2021-2025 | |
| Glaxosmithkline, LLC. | $570.15 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Supernus Pharmaceuticals, INC. | $505.23 | 2021-2025 | Qelbree, Qelbree, Xyosted |
| Xeris Pharmaceuticals, INC. | $306.70 | 2022-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $296.07 | 2019-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $289.87 | 2019-2025 | Eliquis |
| Antares Pharma, INC. | $286.58 | 2019-2025 | Xyosted |
| Amgen INC. | $280.58 | 2020-2025 | Krystexxa, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $261.10 | 2020-2025 | Trintellix |
| Idorsia Pharmaceuticals US INC | $260.76 | 2023-2024 | Quviviq |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Esterle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.